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OBJECTIVE — Lipocalin-2, a novel adipokine, has been shown to be elevated in obese,
insulin-resistant, and diabetic subjects. We therefore sought to study the ex vivo and in vivo
effects of insulin on lipocalin-2 levels in humans.
RESEARCH DESIGN AND METHODS — We investigated the in vivo effects of insulin
(hyperinsulinemia)oncirculatinglipocalin-2levelsbyenzyme-linkedimmunosorbentassayvia
a prolonged insulin-glucose infusion. The ex vivo effect of insulin on adipose tissue lipocalin-2
protein production and secretion into conditioned media was assessed by Western blotting and
enzyme-linked immunosorbent assay, respectively.
RESULTS — Hyperinsulinemic induction in human subjects signiﬁcantly increased circulat-
ing lipocalin-2 levels (P  0.01). Also, in omental adipose tissue explants, insulin caused a
signiﬁcant dose-dependent increase in lipocalin-2 protein production and secretion into condi-
tioned media (P  0.05, P  0.01, respectively); these effects were negated by both phospha-
tidylinositol 3-kinase and mitogen-activated protein kinase kinase inhibitors.
CONCLUSIONS — Lipocalin-2 is upregulated by insulin via phosphatidylinositol 3-kinase
and mitogen-activated protein kinase signaling pathways.
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O
besity and the metabolic syndrome
are associated with serious cardio-
metabolic sequelae including insulin
resistance,hyperinsulinemia,diabetes,dys-
lipidemia, and cardiovascular disease (1).
The metabolic syndrome is associated with
visceral obesity. Adipose tissue produces
cytokines termed “adipokines” that are im-
plicated in the pathogenesis of the meta-
bolic syndrome (2).
Recently, Yan et al. (3) established li-
pocalin-2asanoveladipokine,highlyex-
pressed by adipose tissue in murine
models of obesity. Also, they demon-
strated that lipocalin-2 levels are in-
creased by dexamethasone and tumor
necrosis factor- and are reduced by ros-
iglitazone in murine adipocytes (3). More
recently,Wangetal.(4)reportedelevated
levels of lipocalin-2 in obesity and diabe-
tes.
We therefore studied the effects of
acute and chronic hyperinsulinemia on
circulating lipocalin-2 levels via a pro-
longed insulin-glucose infusion in hu-
mans. We also assessed the effects of
insulin on lipocalin-2 protein production
and secretion into conditioned media
from human visceral adipose tissue
explants.
RESEARCH DESIGN AND
METHODS— We measured circulat-
ing lipocalin-2 in six healthy subjects
(mean  SD age 26.5  8 years and BMI
23.2  2.5 kg/m
2). To account for the
possible diurnal variation in lipocalin-2
levels, we obtained a daily control curve
by measuring fasting lipocalin-2 levels at
30-min intervals from 0800 to 1000 h.
Subsequently, lipocalin-2 levels were
measured at 2-h intervals until 2400 h
and then at 0400 h as well as at 30-min
intervals from 0800 to 1000 h on day 2.
On the following day, the same subjects
were subjected to a prolonged insulin-
glucose infusion for 26 h beginning at
0800h.Insulin(humanActrapid)wasad-
ministered intravenously as a priming
dose of 0.04 units/kg followed by contin-
uous infusion of 0.5 mU   kg
1   min
1.
By choosing this rate of insulin infusion,
we expected to achieve hyperinsulinemia
with an approximate four- to sixfold ele-
vation of basal insulinemia (5). Fasting
blood samples were drawn at 30-min in-
tervalsbetween0800and1000honday1
and day 2 of the prolonged insulin-
glucose infusion (the ﬁrst and the last 2 h
of the infusion). Intermediate blood sam-
ples were taken at 2-h intervals until
2400 h and then at 0400 h on day 2. Glu-
cose levels were maintained between 4.0
and 6.0 mmol/l.
For adipose tissue explant studies, af-
ter an overnight fast, adipose tissue was
obtained (0800–1000 h) from six surgi-
cal patients (age 27.5  7 years and BMI
23.8  2.8 kg/m
2). Samples were placed
intosterilecontainerscontainingMedium
199 (Sigma-Aldrich, Gillingham, U.K.)
for primary adipose tissue culture.
Exclusion criteria for all subjects in-
cluded known cardiovascular disease,
thyroid disease, neoplasms, current
smoking, diabetes, hypertension (blood
pressure 140/90 mmHg), and renal im-
pairment (serum creatinine 120 mol/
l). None of the subjects was on any
medications for 6 months before the
study, including glucocorticoids, antidia-
betes drugs, antiobesity drugs, and lipid-
lowering agents or antihypertensive
medication. The local research ethics
committee approved the study, and all
patients involved gave their informed
consent, in accordance with the guide-
linesintheDeclarationofHelsinki,2000.
Assays
Serum insulin levels were measured by
radioimmunoassay (Pharmacia, Milton
Keynes, U.K.). Lipocalin-2 in serum and
conditioned media from human omental
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DIABETES CARE, VOLUME 32, NUMBER 1, JANUARY 2009 129Figure1—A:Meanconcentrationsoflipocalin-2inng/mlinallsubjectsbeforeandafterinsulininfusion.DataaremeansSD.GroupcomparisonbyStudent’s
ttest.**P0.01.B:Dose-dependenteffectsofinsulin(10
11,10
9,and10
7mol/l)onlipocalin-2proteinproductioninhumanomentaladiposetissueexplants
at24hwereassessedbyWesternblotting.Westernblotanalysisofproteinextractsfromomentaladiposetissuedemonstratesthattheantibodyagainstlipocalin-2
andtheantibodyagainst-actinrecognizedbandswithapparentmolecularweightsof23and45kDa,respectively.Densitometricanalysisoflipocalin-2immune
complexesnormalizedto-actinrevealedthatproteinlevelsoflipocalin-2weresigniﬁcantlyincreasedbyinsulin(10
9and10
7mol/l)inhumanomentaladipose
tissueexplants.Dataareexpressedaspercentdifferenceofmedianofbasal.Eachexperimentwascarriedoutwithsixdifferentsamplesfromsixdifferentsubjectsin
three replicates. Group comparison was by Friedman’s ANOVA and post hoc Dunn’s test. *P  0.05; **P  0.001. PSL, phosphostimulated light units. C:
Dose-dependenteffectsofinsulin(10
11,10
9,and10
7mol/l)onlipocalin-2secretionintoconditionedmediafromhumanomentaladiposetissueexplantsat24h
weremeasuredbyELISA.Lipocalin-2secretionwassigniﬁcantlyincreasedby(10
9and10
7mol/l)humanomentaladiposetissueexplants.Dataareexpressed
aspercentdifferenceofmedianofbasal.Eachexperimentwascarriedoutwithsixdifferentsamplesfromsixdifferentsubjectsinthreereplicates.Groupcomparison
was by Friedman’s ANOVA and post hoc Dunn’s test. *P0.05; **P0.001. D: Effect of PI3K (LY294002) and MEK (U0126) inhibitors on insulin-induced
lipocalin-2proteinproductioninhumanomentaladiposetissueexplantsat24hwasassessedbyWesternblottingandcomparedwithinsulin(10
7mol/l)without
inhibitors.Westernblotanalysisofproteinextractsfromomentaladiposetissuedemonstratesthattheantibodyagainstlipocalin-2andtheantibodyagainst-actin
recognizedbandswithapparentmolecularweightsof23and45kDa,respectively.Densitometricanalysisoflipocalin-2immunecomplexesnormalizedto-actin
revealedthatinsulin-inducedlipocalin-2proteinproductionwassigniﬁcantlydecreasedbyLY294002andU0126inhumanomentaladiposetissueexplants.Data
are expressed as percent difference of median of basal. Each experiment was carried out with six different samples from six different subjects in three replicates.
DifferencesbetweengroupswereassessedusingtheMann-WhitneyUtest.**P0.01;##P0.01.E:EffectofPI3K(LY294002)andMEK(U0126)inhibitorson
insulin-inducedlipocalin-2levelsinconditionedmediafromhumanomentaladiposetissueexplantsat24hwasassessedbyELISAandcomparedwithinsulin(10
7
mol/l) without inhibitors. Lipocalin-2 secretion into conditioned media was signiﬁcantly decreased by LY294002 and U0126 from human omental adipose
tissue explants. Data are expressed as percent difference of median of basal. Each experiment was carried out with six different samples from six
different subjects in three replicates. Differences between groups were assessed using the Mann-Whitney U test. **P  0.01; ##P  0.01.
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ELISA (R&D Systems, Abingdon, U.K.),
according to the manufacturer’s protocol,
withanintra-assaycoefﬁcientofvariation
of 5%.
Primary explant culture
Adipose tissue explants were cultured
with or without the addition of insulin
(Sigma-Aldrich), mitogen-activated pro-
tein kinase kinase (MEK) inhibitor
(U0126; Calbiochem, San Diego, CA), or
phosphatidylinositol 3-kinase (PI3K) in-
hibitor (LY294002; Calbiochem) as pre-
viously described (6).
Western blotting
Protein lysates were prepared and West-
ern blotting was performed as previously
described (6). We used monoclonal pri-
mary mouse anti-human antibody for li-
pocalin-2 (Abcam, Cambridge, U.K.) (1:
500 dilution) and monoclonal primary
rabbit anti-human antibody for -actin
(Cell Signaling Technology, Beverly, MA)
(1:1,000 dilution).
Statistics
Data were analyzed by Student’s t test,
Mann-Whitney U test, and/or Friedman’s
ANOVA according to the number of
groups compared. P  0.05 was consid-
ered signiﬁcant.
RESULTS— Insulin infusion resulted
in elevation of fasting insulinemia from
78.1  12.0 pmol/l to 294.6  31.0
pmol/l. Insulin levels remained elevated
until the end of the prolonged insulin-
glucose infusion (366.0  37.0 pmol/l).
Lipocalin-2 levels remained unaltered
throughout the control day from 91.2 
21.5 ng/ml between 0800 and 1000 h to
82.8  21.9 ng/ml between 0800 and
1000 h the next day (Fig. 1A; P  0.05).
Therewasaprofoundeffectofinsulin
on lipocalin-2 levels over 26 h of insulin
infusion: from 103.2  17.9 ng/ml be-
tween 0800 and 1000 h to 159.7  34.5
ng/ml between 0800 and 1000 h the fol-
lowing day (Fig. 1A; P  0.01). The in-
crease in lipocalin-2 levels was relatively
acute approaching maximal values at 4 h
(180.8  45.7 ng/ml) (Fig. 1A; P  0.01)
and persisting throughout the entire pe-
riod of hyperinsulinemia.
Lipocalin-2 protein production and
secretion into conditioned media were
signiﬁcantly increased dose dependently
by insulin from human omental adipose
tissueexplants;theseeffectswerenegated
by both PI3K inhibitor (LY294002; 50
mol/l) and MEK inhibitor (U0126; 10
mol/l) (Fig. 1B–E;* P  0.05, **P 
0.01, ##P  0.01). Treatment of adipose
tissue explants with either LY294002 or
U0126 alone did not affect lipocalin-2
levels (data not shown).
CONCLUSIONS — Our ﬁndings high-
light the involvement of both PI3K and
mitogen-activated protein kinase signal-
ing pathways in insulin-induced lipoca-
lin-2 production and may explain the
increased lipocalin-2 levels in hyperinsu-
linemic subjects (4). Our observations
may have clinical/therapeutic applica-
tions, given that lipocalin-2 promotes in-
sulin resistance in adipocytes and
hepatocytes (3).
It should be emphasized that our
study utilized relatively small numbers of
subjectsbecauseofthechallengeimposed
bytheprolongedinsulin-glucoseinfusion
study. Additionally, we studied a rela-
tively short-term effect of hyperinsulin-
emia (24 h) in healthy subjects because
type 2 diabetes and insulin resistance syn-
dromes are more chronic states of hyperin-
sulinemia. Nevertheless, our observations
are highly consistent and signiﬁcant and
raise interesting questions on the mecha-
nisms regulating lipocalin-2 production.
In conclusion, we show for the ﬁrst
time the potent and robust regulation of
lipocalin-2 by insulin ex vivo and in vivo.
Our ﬁndings provide novel insights into
lipocalin-2 physiology, which may be
pertinent to hyperinsulinemic states such
as obesity and diabetes.
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